Pediatric off-patent cancer drug studies
Executive Summary
Status of studies for off-patent drugs for pediatric oncology indications will be discussed by FDA's Pediatric Oncology Subcommittee at an Oct. 20 meeting. The committee will also address pediatric post-marketing studies for products approved for oncologic indications and the structure and function of the Office of Oncology Drug Products. The meeting will be held at the CDER advisory committee conference room at 5630 Fishers Lane in Rockville, Md. beginning at 8 a.m...